Dr Jeffrey Barrett
Former Director of the COVID-19 Genomics Initiative at the Wellcome Sanger Institute
This person is a member of Sanger Institute Alumni.
Dr Jeffrey Barrett left the Sanger Institute’s COVID-19 Genomics Initiative in December 2021 to become Chief Scientific Officer at Nightingale Health.
This page is no longer being updated and is a historical record of Jeffrey Barrett’s work at the Sanger Institute.
Jeff rejoined the Wellcome Sanger Institute in 2020 to help build the Sanger Institute’s comprehensive Covid-19 genomic surveillance programme in the UK. Previously Jeff was Director of Open Targets, an open innovation partnership to use cutting-edge genomic results to improve the early stages of drug development. His research team at Sanger analyzed thousands of genomes to better understand the biology of a wide range of complex disorders.
I believe that our rapidly advancing understanding of the genetics of complex diseases has the power to transform how we make new medicines, and prescribe them to the right patients. By collaborating with clinicians around the UK, my team combined the analysis of whole genome sequencing with functional genomics data from the right cells in the right context to connect genetics to biology.
I became interested in human disease genetics during a research project in Mark Daly’s lab at the Whitehead Institute while I was a student at MIT. After graduating I joined Mark’s group full-time where I developed software tools, including the widely used Haploview program. As I became interested in pursuing genetics as a career, I moved to Lon Cardon’s group in Oxford for a D. Phil in Statistics. I helped design the first generation of genome-wide association studies (GWAS), and was a lead analyst for the Wellcome Trust Case Control Consortium. Contrary to my assumption that I’d move back to the States, I couldn’t turn down a post-doc opportunity in David Clayton’s group in Cambridge, where I worked on meta-analyses and follow-up of GWAS in both inflammatory bowel disease and type 1 diabetes, each of which resulted in the identification of twenty novel associations.
I moved to the Sanger Institute in November 2008 to start a team in medical genomics (and committing myself to the UK for the long haul!). My team has used GWAS as a tool to explore the overlapping genetic architecture of diseases of inflammation, immunity, and infection including celiac disease, inflammatory bowel disease, multiple sclerosis, tuberculosis and malaria. More recently, the team has also analyzed large scale exome-sequencing datasets to probe the contribution of rare genetic variation in developmental disorders, autism and schizophrenia.
My leadership roles have included editorships at Bioinformatics and Human Molecular Genetics, the management committees of the WTCCC3, UK10K and DDD studies, and co-chairmanship of the International IBD Genetics Consortium.
Left the Sanger Institute to become CSO at Nightingale Health
Rejoined the Sanger Institute as Lead Covid-19 Statistical Geneticist
Left the Wellcome Sanger Institute and Open Targets to become CSO at Genomics Plc
Appointed Founding Director of Open Targets
Joined Sanger Institute
Postdoc with David Clayton on GWAS meta-analyses
Moved to Oxford
Fulfilled dream as Bostonian: saw Red Sox win World Series at Fenway Park
Haploview software released
Graduated from MIT with BS in physics
First genomics job: correcting sequencing gel lane alignment
Programmes and Facilities
Parasites and Microbes
We use genomics to study important problems in infectious disease, with a strong desire to develop and refine tools for disease ...